Additionally, recent data from the NYU, ADNI and NACC cohorts suggests an early preclinical stage, marked by CSF elevations in tau accompanied by elevations in CSF Aβ42 which were largely observed in younger age quartiles (between 45 and 70 years of age), indicating that elevated CSF Aβ42 might also be associated with very early preclinical AD risk [55]. Here, MAPT is linked to Alzheimer disease.